SCHEMBL17329258

SCHEMBL17329258

O=C(Nc1ccc(S(=O)(=O)N[C@H]2CCOC2=O)cc1)c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.56
KMT2A Q03164 8/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
TSHR P16473 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
MAOB P27338 1/20 0.46
PTPN1 P18031 1/20 0.46
MITF O75030 1/20 0.45
CXCR2 P25025 1/20 0.44
ENPP1 P22413 1/20 0.44
ENPP2 Q13822 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17329259 1.00 MEN1 (0.56) MEN1KMT2ASMN1; SMN2LMNATSHR
SCHEMBL17329201 0.89 MEN1 (0.56) MEN1KMT2ASMN1; SMN2LMNARAB9A
SCHEMBL17329200 0.89 MEN1 (0.56) MEN1KMT2ASMN1; SMN2LMNARAB9A
SCHEMBL17329223 0.89 MEN1 (0.47) MEN1KMT2ASMN1; SMN2LMNATSHR
SCHEMBL17329230 0.89 MEN1 (0.52) MEN1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL17329224 0.89 MEN1 (0.47) MEN1KMT2ASMN1; SMN2LMNATSHR
SCHEMBL17329231 0.89 MEN1 (0.52) MEN1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL17329183 0.89 PRMT1 (0.52) MEN1KMT2ALMNA
SCHEMBL17329184 0.89 PRMT1 (0.52) MEN1KMT2ALMNA
SCHEMBL17329248 0.87 KMT2A (0.52) MEN1KMT2ASMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630939-B2 Derivative of homoserine lactone, and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 US claimed
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-12-24 US claimed
EP-2955174-A1 DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2015-12-16 EP claimed
US-9630939-B2 Derivative of homoserine lactone, and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 US disclosed
US-9630939-B2 Derivative of homoserine lactone, and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 US disclosed
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-12-24 US disclosed
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2015-12-24 US disclosed
EP-2955174-A1 DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2015-12-16 EP disclosed
EP-2955174-A1 DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2015-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368217-A1 Derivative of Homoserine Lactone, and Preparation Method and Use Thereof LSS, HES1, SOS1 MEN1 589/4885KMT2A 3880/4885SMN1; SMN2 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.